{"url":"https://lda.gov/api/v1/filings/70114262-5c99-402a-bc3e-c9251b4155c3/","filing_uuid":"70114262-5c99-402a-bc3e-c9251b4155c3","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/70114262-5c99-402a-bc3e-c9251b4155c3/print/","filing_document_content_type":"text/html","income":null,"expenses":"560000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Elizabeth Grammer","dt_posted":"2026-04-20T11:56:25-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"34175 Ardenwood Boulevard","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Fremont","registrant_state":"CA","registrant_zip":"94555","registrant":{"id":401105832,"url":"https://lda.gov/api/v1/registrants/401105832/","house_registrant_id":null,"name":"ARDELYX, INC.","description":"Biopharmaceutical company","address_1":"34175 Ardenwood Boulevard","address_2":null,"address_3":null,"address_4":null,"city":"Freemont","state":"CA","state_display":"California","zip":"94555","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ELIZABETH GRAMMER","contact_telephone":"+1 510-745-1705","dt_updated":"2026-07-30T15:45:39.643015-04:00"},"client":{"id":207922,"url":"https://lda.gov/api/v1/clients/207922/","client_id":12,"name":"ARDELYX, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-10-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Access to innovative kidney treatments, ESRD PPS, coverage of oral only medications for people with ESRD, innovation, Drug pricing, Medicare access to pharmaceuticals.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142055,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"PEREIRA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150642,"prefix":null,"prefix_display":null,"first_name":"THERESA","nickname":null,"middle_name":null,"last_name":"JOLIVETTE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147593,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LASH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148292,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"KRIBS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}